Zurueck zur Suche

Reporte zur Charge U7207AA

Verknuepft ueber VAERS_ID mit VAERSDATA, Vax und Symptoms

17Reporte angezeigt
0Todesfaelle
0Hospitalisiert
0Lebensbedrohlich
0Bleibende Schaeden
CA 6 AZ 2 PA 2 NV 2 TX 2 MA 1 NJ 1 NM 1

VAERS 2305840

SANOFI PASTEUR · MENINGOCOCCAL CONJUGATE (MENACTRA) · Charge U7207AA

schwer
Staat
AZ
Alter
16,0
Geschlecht
F
Eingang
12.08.2022
Impfdatum
01.06.2022
Beginn
01.06.2022
Tage bis Beginn
0,0
Dosis
2
Route/Site
SYR / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Abdominal pain upper Cataplexy Dyspnoea Loss of consciousness Musculoskeletal stiffness Dizziness Syncope Seizure

Symptomtext

Had a syncopal event within a minute after the vaccines were administered. She felt lightheaded, passed out on the exam table and had some stiffening movements of her arms and was unconscious for a reported minute. When she awoke she was shaking, very tearful and felt ill to her stomach. She was kept recumbent for about 15 minutes, given a cool cloth for her head; a drink of water and a popsicle. She reported that she had not eaten anything for breakfast or had anything to drink that morning. She continued to feel tired and exhausted. After about 20 minutes was helped to her car, reclined in the seat. After returning home, she was reported to have slept most of the afternoon and hadn't had much to eat by late afternoon. The following morning, she was reported to be feeling better.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Loss of consciousness
Hospital-Tage
-
Labordaten
None
Aktuelle Erkrankungen
None
Vorgeschichte
Chronic abdominal pain, on and off
Andere Medikamente
None known.
Allergien
None
Vorherige Impfungen
-

VAERS 2361272

SANOFI PASTEUR · MENINGOCOCCAL CONJUGATE (MENACTRA) · Charge U7207AA

schwer
Staat
PA
Alter
16,0
Geschlecht
F
Eingang
07.07.2022
Impfdatum
07.07.2022
Beginn
07.07.2022
Tage bis Beginn
0,0
Dosis
2
Route/Site
IM / RA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: ja Erholt: nein
Blindness Blood glucose normal Generalised tonic-clonic seizure Hypoaesthesia Loss of consciousness

Symptomtext

Vaccine given at 1409, 1410 passed out and came to within 30 seconds. 1413 physician notice tonic clonic seizure like movements to right arm for about 30 seconds. Following this patient complained of complete loss of vision, loss of feeling in hands and feet for 10 minutes. Transported to ER via ambulance

Weitere VAERSDATA-Felder
Praegender Schweregrund
Generalised tonic-clonic seizure
Hospital-Tage
-
Labordaten
Blood glucose 103
Aktuelle Erkrankungen
none
Vorgeschichte
Irregular PEriods History of anorexia
Andere Medikamente
none
Allergien
none
Vorherige Impfungen
-

VAERS 2119699

SANOFI PASTEUR · MENINGOCOCCAL CONJUGATE (MENACTRA) · Charge U7207AA

mild
Staat
NV
Alter
-
Geschlecht
F
Eingang
09.07.2022
Impfdatum
10.02.2022
Beginn
11.02.2022
Tage bis Beginn
1,0
Dosis
1
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Injection site erythema Injection site pruritus Injection site swelling Wrong technique in product usage process

Symptomtext

Menactra and YF-Vax administered on the same day in the same site as RabAvert; Redness; Swelling; Itchiness around injection site; Injection site erythema; injection site swelling; Case reference number US-BN-2022-000225, initially downloaded from Vaccine Adverse Event Reporting System (VAERS) on 07-Mar-2022, is a spontaneous case received from other health professional via health authority VAERS (Worldwide Unique Identifier 2119699-1) and concerns a 28-year-old female patient. The patient's medical history and concomitant medication details were not provided. On 10-Feb-2022, the patient was vaccinated with the first dose of RabAvert (inactivated rabies virus vaccine, batch number: ARBA911D), at an unknown dose, administered intramuscularly in the left arm and for unknown indication, with co-suspects Menactra (meningococcal vaccine, batch number: U7207AA) administered intramuscularly and YF-Vax (yellow fever vaccine, batch number: UJ397AA) administered subcutaneously, both at an unknown dose, administered in the left arm and for unknown indication (explicitly coded as 'Vaccination error'). On 11-Feb-2022, one day after the first dose, the patient experienced redness, swelling, itchiness around the injection site, injection site erythema and injection site swelling. At the time of this report, the patient was recovering from the events of 'redness', 'swelling', 'injection site erythema', 'injection site swelling' and 'injection site itching', reported as improving and only mildly itchy. The reporter assessed all the events as non-serious. Causality assessment was not provided. No further information was provided.; Reporter's Comments: A 28-year-old female patient was vaccinated with the first dose of RabAvert administered intramuscularly in the left arm along with co-suspects Menactra, administered intramuscularly and YF-Vax, administered subcutaneously, both administered at the same site, which is considered as vaccination error. One day after the first dose, the patient experienced erythema, swelling, injection site pruritus, injection site erythema and injection site swelling. Erythema, swelling, injection site pruritus, injection site erythema and injection site swelling are all listed for Rabipur according to Datasheet, whilst vaccination error is listed per company convention. The patient's medical history and concomitant medication details were not provided. Co-suspect vaccines Menactra and YF-Vax may have contributed to all reported events. However, having in mind the plausible temporal relationship and well known product safety profile, the causality for all reported events is assessed as related to Rabipur. Vaccination error is not related to Rabipur, but to a human factor. The case is non-serious.; Sender's Comments: A 28-year-old female patient was vaccinated with the first dose of RabAvert administered intramuscularly in the left arm along with co-suspects Menactra, administered intramuscularly and YF-Vax, administered subcutaneously, both administered at the same site, which is considered as vaccination error. One day after the first dose, the patient experienced erythema, swelling, injection site pruritus, injection site erythema and injection site swelling. Erythema, swelling, injection site pruritus, injection site erythema and injection site swelling are all listed for Rabipur according to Datasheet, whilst vaccination error is listed per company convention. The patient's medical history and concomitant medication details were not provided. Co-suspect vaccines Menactra and YF-Vax may have contributed to all reported events. However, having in mind the plausible temporal relationship and well known product safety profile, the causality for all reported events is assessed as related to Rabipur. Vaccination error is not related to Rabipur, but to a human factor. The case is non-serious.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Injection site erythema
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
Comments: None
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2119699

SANOFI PASTEUR · MENINGOCOCCAL CONJUGATE (MENACTRA) · Charge U7207AA

mild
Staat
NV
Alter
-
Geschlecht
F
Eingang
09.07.2022
Impfdatum
10.02.2022
Beginn
11.02.2022
Tage bis Beginn
1,0
Dosis
UNK
Route/Site
OT / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Injection site erythema Injection site pruritus Injection site swelling Wrong technique in product usage process

Symptomtext

Menactra and YF-Vax administered on the same day in the same site as RabAvert; Redness; Swelling; Itchiness around injection site; Injection site erythema; injection site swelling; Case reference number US-BN-2022-000225, initially downloaded from Vaccine Adverse Event Reporting System (VAERS) on 07-Mar-2022, is a spontaneous case received from other health professional via health authority VAERS (Worldwide Unique Identifier 2119699-1) and concerns a 28-year-old female patient. The patient's medical history and concomitant medication details were not provided. On 10-Feb-2022, the patient was vaccinated with the first dose of RabAvert (inactivated rabies virus vaccine, batch number: ARBA911D), at an unknown dose, administered intramuscularly in the left arm and for unknown indication, with co-suspects Menactra (meningococcal vaccine, batch number: U7207AA) administered intramuscularly and YF-Vax (yellow fever vaccine, batch number: UJ397AA) administered subcutaneously, both at an unknown dose, administered in the left arm and for unknown indication (explicitly coded as 'Vaccination error'). On 11-Feb-2022, one day after the first dose, the patient experienced redness, swelling, itchiness around the injection site, injection site erythema and injection site swelling. At the time of this report, the patient was recovering from the events of 'redness', 'swelling', 'injection site erythema', 'injection site swelling' and 'injection site itching', reported as improving and only mildly itchy. The reporter assessed all the events as non-serious. Causality assessment was not provided. No further information was provided.; Reporter's Comments: A 28-year-old female patient was vaccinated with the first dose of RabAvert administered intramuscularly in the left arm along with co-suspects Menactra, administered intramuscularly and YF-Vax, administered subcutaneously, both administered at the same site, which is considered as vaccination error. One day after the first dose, the patient experienced erythema, swelling, injection site pruritus, injection site erythema and injection site swelling. Erythema, swelling, injection site pruritus, injection site erythema and injection site swelling are all listed for Rabipur according to Datasheet, whilst vaccination error is listed per company convention. The patient's medical history and concomitant medication details were not provided. Co-suspect vaccines Menactra and YF-Vax may have contributed to all reported events. However, having in mind the plausible temporal relationship and well known product safety profile, the causality for all reported events is assessed as related to Rabipur. Vaccination error is not related to Rabipur, but to a human factor. The case is non-serious.; Sender's Comments: A 28-year-old female patient was vaccinated with the first dose of RabAvert administered intramuscularly in the left arm along with co-suspects Menactra, administered intramuscularly and YF-Vax, administered subcutaneously, both administered at the same site, which is considered as vaccination error. One day after the first dose, the patient experienced erythema, swelling, injection site pruritus, injection site erythema and injection site swelling. Erythema, swelling, injection site pruritus, injection site erythema and injection site swelling are all listed for Rabipur according to Datasheet, whilst vaccination error is listed per company convention. The patient's medical history and concomitant medication details were not provided. Co-suspect vaccines Menactra and YF-Vax may have contributed to all reported events. However, having in mind the plausible temporal relationship and well known product safety profile, the causality for all reported events is assessed as related to Rabipur. Vaccination error is not related to Rabipur, but to a human factor. The case is non-serious.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Injection site erythema
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
Comments: None
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2311684

SANOFI PASTEUR · MENINGOCOCCAL CONJUGATE (MENACTRA) · Charge U7207AA

mild
Staat
TX
Alter
11,0
Geschlecht
M
Eingang
07.06.2022
Impfdatum
02.06.2022
Beginn
03.06.2022
Tage bis Beginn
1,0
Dosis
1
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Body temperature increased Injection site erythema Injection site pain Injection site swelling

Symptomtext

L arm became red, swollen and painful. Symptoms began around 0200am. Patient had TMAX 101 x 48 hrs post onset. Symptoms started approx 10 hrs after administration of vaccine.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Injection site erythema
Hospital-Tage
-
Labordaten
None
Aktuelle Erkrankungen
None
Vorgeschichte
Seasonal Allergies
Andere Medikamente
None
Allergien
None
Vorherige Impfungen
-

VAERS 2162091

SANOFI PASTEUR · MENINGOCOCCAL CONJUGATE (MENACTRA) · Charge U7207AA

mild
Staat
PA
Alter
37,0
Geschlecht
F
Eingang
25.02.2022
Impfdatum
23.02.2022
Beginn
24.02.2022
Tage bis Beginn
1,0
Dosis
UNK
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: unbekannt
Arthritis Axillary pain

Symptomtext

Pain in the Arm pit and Sholder

Weitere VAERSDATA-Felder
Praegender Schweregrund
Axillary pain
Hospital-Tage
-
Labordaten
N/A
Aktuelle Erkrankungen
Denied
Vorgeschichte
Denied
Andere Medikamente
Tylenol
Allergien
Denied
Vorherige Impfungen
-

VAERS 2584399

SANOFI PASTEUR · MENINGOCOCCAL CONJUGATE (MENACTRA) · Charge U7207AA

gering
Staat
CA
Alter
12,0
Geschlecht
F
Eingang
20.02.2023
Impfdatum
16.02.2023
Beginn
16.02.2023
Tage bis Beginn
0,0
Dosis
1
Route/Site
OT / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Expired product administered Medication error No adverse event

Symptomtext

patient was administered expired MENACTRA that expired 8 days ago with no reported adverse event; Initial information received on 16-Feb-2023 regarding an unsolicited valid non-serious case received from a healthcare professional. This case involves a 12-year-old female patient who was administered expired MENINGOCOCCAL A-C-Y-W135 (D CONJ) VACCINE [MENACTRA] that expired 8 days ago with no reported adverse event. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. Concomitant medications included HPV VACCINE VLP RL1 4V (YEAST) (GARDASIL) for Immunisation; and DIPHTHERIA VACCINE TOXOID, PERTUSSIS VACCINE ACELLULAR, TETANUS VACCINE TOXOID (TDAP) for Immunisation. On 16-Feb-2023, the patient received dose 1 at 0.5ml total of suspect MENINGOCOCCAL A-C-Y-W135 (D CONJ) VACCINE (Strength: standard; formulation: unknown) (lot number: U7207AA, expiry date: 08-Feb-2023) via intramuscular route in left deltoid for Immunization and on the same day patient was administered expired menactra that expired 8 days ago with no reported adverse event (expired product administered). It was reported, caller requesting information on MENACTRA. Wanting to know next steps to take. This situation is reported as a medication error due to expired MENACTRA being administered to a patient Action taken with MENINGOCOCCAL VACCINE (MENACTRA) was not applicable. At time of reporting, the outcome was Unknown. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Expired product administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
GARDASIL; TDAP
Allergien
-
Vorherige Impfungen
-

VAERS 2486883

SANOFI PASTEUR · MENINGOCOCCAL CONJUGATE (MENACTRA) · Charge U7207AA

gering
Staat
MA
Alter
16,0
Geschlecht
M
Eingang
24.10.2022
Impfdatum
20.10.2022
Beginn
20.10.2022
Tage bis Beginn
0,0
Dosis
2
Route/Site
IM / RA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
No adverse event Wrong product administered

Symptomtext

Pt given COVID bivalent booster as first dose in series. No adverse reaction, RN confirmed CDC recommendations and spoke with pts father regarding event. Father has no further questions.

Weitere VAERSDATA-Felder
Praegender Schweregrund
No adverse event
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
None
Vorgeschichte
None
Andere Medikamente
None
Allergien
None
Vorherige Impfungen
-

VAERS 2469833

SANOFI PASTEUR · MENINGOCOCCAL CONJUGATE (MENACTRA) · Charge U7207AA

gering
Staat
AZ
Alter
11,0
Geschlecht
M
Eingang
05.10.2022
Impfdatum
01.09.2022
Beginn
01.09.2022
Tage bis Beginn
0,0
Dosis
1
Route/Site
IM / RA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: unbekannt
Expired product administered No adverse event

Symptomtext

Expired vaccine given to client on 09/01/22 and vaccine expired 08/31/22. No adverse symptoms occurred that day of vaccination or thereafter that I am aware of. Contacted client of expired vaccine given.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Expired product administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
No Known Drug Allergies.
Vorherige Impfungen
-

VAERS 2387778

SANOFI PASTEUR · MENINGOCOCCAL CONJUGATE (MENACTRA) · Charge U7207AA

gering
Staat
NJ
Alter
18,0
Geschlecht
F
Eingang
24.07.2022
Impfdatum
13.07.2022
Beginn
13.07.2022
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
- / RA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Medication error No adverse event Vaccination error

Symptomtext

co-administering Menactra with Covid-19 (with no reported adverse event); use of Menactra instead of the intended vaccine against meningococcal B (with no reported adverse event); Initial information received on 13-Jul-2022 regarding an unsolicited valid non-serious case received from a other health professional. This case involves a 18 years old female patient who was co-administering menactra with covid-19 (with no reported adverse event) and use of menactra instead of the intended vaccine against meningococcal b (with no reported adverse event) while receiving vaccine MENINGOCOCCAL A-C-Y-W135 (D CONJ) VACCINE [MENACTRA]. The patient's past vaccination(s) included MENVEO on 17-JUN-2015 with first dose and MENVEO on 29-JAN-2020 with second dose. The patient's past medical history, medical treatment(s) and family history were not provided. Concomitant medications included COVID-19 VACCINE (COVID-19 VACCINE) for Immunisation. On 13-Jul-2022, the patient received an unknown dose of suspect MENINGOCOCCAL A-C-Y-W135 (D CONJ) VACCINE (formulation, strength, route: unknown) lot U7207AA, expiration date:08-Feb-2023, in the right arm as immunization. On 13-JUL-2022 the patient was co-administering menactra with covid-19 (with no reported adverse event) (vaccine coadministration) and there was use of menactra instead of the intended vaccine against meningococcal b (with no reported adverse event) (vaccination error) same day following the administration of MENINGOCOCCAL A-C-Y-W135 (D CONJ) VACCINE. Action taken was not applicable. It was not reported if the patient received a corrective treatment for all the events. At time of reporting, the outcome was Unknown for the events. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the guidelines. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Medication error
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2393619

SANOFI PASTEUR · MENINGOCOCCAL CONJUGATE (MENACTRA) · Charge U7207AA

gering
Staat
CA
Alter
11,0
Geschlecht
M
Eingang
22.07.2022
Impfdatum
11.07.2022
Beginn
11.07.2022
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Extra dose administered

Symptomtext

Patient was give T-dap booster he didn't need. No symptoms or reaction day of vaccine given.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Extra dose administered
Hospital-Tage
-
Labordaten
N/A
Aktuelle Erkrankungen
0 None
Vorgeschichte
0 None
Andere Medikamente
N/A
Allergien
0 None
Vorherige Impfungen
-

VAERS 2316703

SANOFI PASTEUR · MENINGOCOCCAL CONJUGATE (MENACTRA) · Charge U7207AA

gering
Staat
CA
Alter
18,0
Geschlecht
F
Eingang
12.06.2022
Impfdatum
07.06.2022
Beginn
08.06.2022
Tage bis Beginn
1,0
Dosis
1
Route/Site
IM / RA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Musculoskeletal stiffness Swelling

Symptomtext

Systemic: neck stiffness-Medium, Additional Details: Around 5:30 PM PST, I received a call from a call center, requesting to talk with the provider. I spoke with the patient and the patient's mother. Patient stated that she developed neck stiffness at night after receiving menactra. The symptom is gradually worse in the morning. Denies rash, shortness of breath or tingling. Pt stated that she feels like having a "bulging" behind her neck. Advised to see return to the clinic today or visit near by urgent care to be further evaluated

Weitere VAERSDATA-Felder
Praegender Schweregrund
Musculoskeletal stiffness
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2310300

SANOFI PASTEUR · MENINGOCOCCAL CONJUGATE (MENACTRA) · Charge U7207AA

gering
Staat
CA
Alter
11,0
Geschlecht
M
Eingang
06.06.2022
Impfdatum
01.06.2022
Beginn
01.06.2022
Tage bis Beginn
0,0
Dosis
1
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
No adverse event Product preparation error

Symptomtext

Pt given 0.2ml of undiluted COVID-19 vaccine (orange cap) in right deltoid. Monitored patient in office. No adverse affects noted.

Weitere VAERSDATA-Felder
Praegender Schweregrund
No adverse event
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
none
Vorgeschichte
none
Andere Medikamente
none
Allergien
none
Vorherige Impfungen
-

VAERS 2201794

SANOFI PASTEUR · MENINGOCOCCAL CONJUGATE (MENACTRA) · Charge U7207AA

gering
Staat
CA
Alter
16,0
Geschlecht
M
Eingang
28.03.2022
Impfdatum
25.03.2022
Beginn
25.03.2022
Tage bis Beginn
0,0
Dosis
2
Route/Site
IM / RA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: unbekannt
Product preparation issue

Symptomtext

Inadvertently administered 0.3 mL of Pfizer Covid-19 5-11yr vaccine (orange top) undiluted.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Product preparation issue
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
Had a cold the week prior to visit.
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2168558

SANOFI PASTEUR · MENINGOCOCCAL CONJUGATE (MENACTRA) · Charge U7207AA

gering
Staat
NM
Alter
16,0
Geschlecht
F
Eingang
09.03.2022
Impfdatum
28.02.2022
Beginn
01.03.2022
Tage bis Beginn
1,0
Dosis
2
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Product storage error

Symptomtext

Vaccine administered was exposed to a low temperature and not supported for administration. Patient has not reported any reactions. Revaccination plan to be initiated.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Product storage error
Hospital-Tage
-
Labordaten
n/a
Aktuelle Erkrankungen
n/a
Vorgeschichte
n/a
Andere Medikamente
n/a
Allergien
n/a
Vorherige Impfungen
-

VAERS 2091419

SANOFI PASTEUR · MENINGOCOCCAL CONJUGATE (MENACTRA) · Charge U7207AA

gering
Staat
TX
Alter
-
Geschlecht
U
Eingang
05.02.2022
Impfdatum
-
Beginn
-
Tage bis Beginn
-
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Medication error Product storage error

Symptomtext

cold temperature excursion refrigerator door was not closed 54 minutes and the lowest temperature reached was 31.2F with no reported adverse event; Initial information received on 26-Jan-2022 regarding an unsolicited valid non-serious case received from a other health professional. This case involves a patient of unknown demographics who had cold temperature excursion refrigerator door was not closed 54 minutes and the lowest temperature reached was 31.2F with no reported adverse event while receiving vaccines DIPHTHERIA-2/TETANUS/5 AC PERTUSSIS VACCINE [ADACEL], IPV (VERO) [IPOL], DIPHTHERIA/TETANUS/5 HYBRID AC PERTUSSIS/IPV(MRC5)/HIB(PRP/T) VACCINE [PENTACEL], MENINGOCOCCAL A-C-Y-W135 (D CONJ) VACCINE [MENACTRA] and DIPHTHERIA-2/TETANUS-5 ADSORBED TOXOIDS NO PRESERVATIVE ADULT [TENIVAC]. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On an unknown date, the patient received an unknown dose of suspect DIPHTHERIA-2/TETANUS-5 ADSORBED TOXOIDS NO PRESERVATIVE ADULT (formulation, strength: unknown) lot U6852AA in unknown administration site as prophylactic vaccination. On an unknown date, the patient received an unknown dose of suspect MENINGOCOCCAL A-C-Y-W135 (D CONJ) VACCINE (formulation, strength: unknown) lot U7207AA in unknown administration site as prophylactic vaccination. On an unknown date, the patient received an unknown dose of suspect DIPHTHERIA/TETANUS/5 HYBRID AC PERTUSSIS/IPV(MRC5)/HIB(PRP/T) VACCINE (formulation, strength: unknown) lot UJ601AAA in unknown administration site as prophylactic vaccination. On an unknown date, the patient received an unknown dose of suspect IPV (VERO) (formulation, strength: unknown) lot T1D482M in unknown administration site as prophylactic vaccination. On an unknown date, the patient received an unknown dose of suspect DIPHTHERIA-2/TETANUS/5 AC PERTUSSIS VACCINE (formulation, strength: unknown) lot C5787AA in unknown administration site as prophylactic vaccination. On an unknown date the patient developed a non-serious event "cold temperature excursion refrigerator door was not closed 54 minutes and the lowest temperature reached was 31.2f with no reported adverse event" (product storage error) (unknown latency) following the administration of all suspect vaccines. It was reported "Caller states that a cold temperature excursion occurred because the refrigerator door was not closed. The total excursion time was for 54 minutes and the lowest temperature reached was 31.2F. The products involved were unopened: TENIVAC, MENACTRA, PENTACEL, IPOL, and ADACEL. Caller asked for stability information for these products." Action taken was not applicable. It was not reported if the patient received a corrective treatment for the event (cold temperature excursion refrigerator door was not closed 54 minutes and the lowest temperature reached was 31.2F with no reported adverse event). At time of reporting, the outcome was Unknown for the event cold temperature excursion refrigerator door was not closed 54 minutes and the lowest temperature reached was 31.2f with no reported adverse event. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Medication error
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2091418

SANOFI PASTEUR · MENINGOCOCCAL CONJUGATE (MENACTRA) · Charge U7207AA

gering
Staat
CA
Alter
-
Geschlecht
U
Eingang
05.02.2022
Impfdatum
-
Beginn
-
Tage bis Beginn
-
Dosis
UNK
Route/Site
OT / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Medication error No adverse event Product storage error

Symptomtext

temperature excursion due to leaving the refrigerator door ajar with no reported adverse event; Initial information received on 26-Jan-2022 regarding an unsolicited valid non-serious case received from a other health professional. This case involves a patient with unknown gender who had temperature excursion due to leaving the refrigerator door ajar with no reported adverse event while receiving vaccines MENINGOCOCCAL A-C-Y-W135 (D CONJ) VACCINE [MENACTRA] and DIPHTHERIA-2/TETANUS/5 AC PERTUSSIS VACCINE [ADACEL]. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On an unknown date, the patient received a dose of suspect DIPHTHERIA-2/TETANUS/5 AC PERTUSSIS VACCINE lot U7117BA via unknown route in unknown administration site. On an unknown date, the patient received a dose of suspect MENINGOCOCCAL A-C-Y-W135 (D CONJ) VACCINE lot U7207AA via unknown route in unknown administration site. On an unknown date the patient had temperature excursion due to leaving the refrigerator door ajar with no reported adverse event (intercepted medication error) (unknown latency) following the administration of DIPHTHERIA-2/TETANUS/5 AC PERTUSSIS VACCINE and (unknown latency) following the administration of MENINGOCOCCAL A-C-Y-W135 (D CONJ) VACCINE. Action taken was not applicable. It was not reported if the patient received a corrective treatment for the event (temperature excursion due to leaving the refrigerator door ajar with no reported adverse event). At time of reporting, the outcome was Unknown for the event temperature excursion due to leaving the refrigerator door ajar with no reported adverse event. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Medication error
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-